LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 13 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 3. - Dataset (ID:20250)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
---|---|---|---|---|---|---|---|---|---|---|---|
MDA-MB-231 | PI103 | 0.37 | uM | LJP6 | 72 | hr | 1235 | 1617 | 4405 | 0.3721 | 0.1286 |
MDA-MB-231 | PI103 | 1.11 | uM | LJP6 | 72 | hr | 1235 | 1835 | 4405 | 0.4173 | 0.2406 |
MDA-MB-231 | PI103 | 3.33 | uM | LJP6 | 72 | hr | 1235 | 1612 | 4405 | 0.3664 | 0.1556 |
MDA-MB-231 | PI103 | 10 | uM | LJP6 | 72 | hr | 1235 | 1139 | 4405 | 0.2586 | -0.0442 |
MDA-MB-231 | Dovitinib | 0.04 | uM | LJP5 | 72 | hr | 1235 | 4560 | 4660 | 0.9773 | 0.9749 |
MDA-MB-231 | Dovitinib | 0.12 | uM | LJP5 | 72 | hr | 1235 | 3912 | 4660 | 0.8390 | 0.8241 |
MDA-MB-231 | Dovitinib | 0.37 | uM | LJP5 | 72 | hr | 1235 | 2602 | 4660 | 0.5562 | 0.4684 |
MDA-MB-231 | Dovitinib | 1.11 | uM | LJP5 | 72 | hr | 1235 | 2184 | 4660 | 0.4681 | 0.3439 |
MDA-MB-231 | Dovitinib | 3.33 | uM | LJP5 | 72 | hr | 1235 | 1938 | 4660 | 0.4162 | 0.2647 |
MDA-MB-231 | Dovitinib | 10 | uM | LJP5 | 72 | hr | 1235 | 1548 | 4660 | 0.3319 | 0.1233 |
MDA-MB-231 | GSK 690693 | 0.04 | uM | LJP5 | 72 | hr | 1235 | 4161 | 4660 | 0.8914 | 0.8820 |
MDA-MB-231 | GSK 690693 | 0.12 | uM | LJP5 | 72 | hr | 1235 | 4227 | 4660 | 0.9062 | 0.8987 |
MDA-MB-231 | GSK 690693 | 0.37 | uM | LJP5 | 72 | hr | 1235 | 4346 | 4660 | 0.9315 | 0.9261 |
MDA-MB-231 | GSK 690693 | 1.11 | uM | LJP5 | 72 | hr | 1235 | 4524 | 4660 | 0.9696 | 0.9668 |
MDA-MB-231 | GSK 690693 | 3.33 | uM | LJP5 | 72 | hr | 1235 | 4823 | 4660 | 1.0351 | 1.0365 |
MDA-MB-231 | GSK 690693 | 10 | uM | LJP5 | 72 | hr | 1235 | 3718 | 4660 | 0.7978 | 0.7771 |
MDA-MB-231 | SNS-032 | 0.04 | uM | LJP6 | 72 | hr | 1235 | 2289 | 4405 | 0.5185 | 0.3954 |
MDA-MB-231 | SNS-032 | 0.12 | uM | LJP6 | 72 | hr | 1235 | 554 | 4405 | 0.1259 | -0.3546 |
MDA-MB-231 | SNS-032 | 0.37 | uM | LJP6 | 72 | hr | 1235 | 489 | 4405 | 0.1109 | -0.3977 |
MDA-MB-231 | SNS-032 | 1.11 | uM | LJP6 | 72 | hr | 1235 | 525 | 4405 | 0.1194 | -0.3735 |
MDA-MB-231 | SNS-032 | 3.33 | uM | LJP6 | 72 | hr | 1235 | 530 | 4405 | 0.1203 | -0.3708 |
MDA-MB-231 | SNS-032 | 10 | uM | LJP6 | 72 | hr | 1235 | 590 | 4405 | 0.1340 | -0.3322 |
MDA-MB-231 | Afatinib | 0.04 | uM | LJP6 | 72 | hr | 1235 | 4254 | 4405 | 0.9654 | 0.9608 |
MDA-MB-231 | Afatinib | 0.12 | uM | LJP6 | 72 | hr | 1235 | 4078 | 4405 | 0.9259 | 0.9175 |
MDA-MB-231 | Afatinib | 0.37 | uM | LJP6 | 72 | hr | 1235 | 3577 | 4405 | 0.8130 | 0.7868 |